Sitagliptin: Is It Effective in Routine Clinical Practice?
Table 1
Baseline demographic and clinical characteristics of patients.
Patients characteristics
Number of patients (%)
Mean (SD) (median) range
Age (years) ()
21–30
3 (0.7)
65 (11.7) (65) 23–100
31–40
9 (2.0)
41–50
33 (7.2)
51–60
104 (22.7)
61–70
152 (33.3)
>70
156 (34.1)
Gender ()
Male
200 (43.8)
Female
257 (56.2)
Ethnic groups ()
Malay
153 (33.5)
Chinese
182 (39.8)
Indian
119 (26.0)
Others
3 (0.7)
Marital status ()
Single
21 (4.9)
Married
392 (90.7)
Divorced
2 (0.5)
Widower
17 (3.9)
Employment status ()
Employed
115 (35.0)
Unemployed
214 (65.0)
Baseline HbA1c (%) (mmol/mol)a ()
<6.5 (<48)
25 (6.2)
8.7 (1.7) (8.5) 4.9–17.1
≥6.5 (≥48)
377 (93.8)
<7.0 (<53)
47 (11.7)
≥7.0 (≥53)
355 (88.3)
Fasting blood glucose (mmol/L) (mg/dL)b ()
<4.4 (<79.2)
6 (1.6)
8.8 (3.2) (8.3) 2.9–36.9
4.4–6.1 (79.2–109.8)
50 (13.4)
>6.1 (>109.8)
317 (85.0)
Presence of comorbiditiesc ()
Hypertension
379 (82.9)
Dyslipidemia
322 (70.5)
Cardiovascular disease
143 (31.3)
Kidney disease
103 (22.5)
Stroke
23 (5.0)
Duration of diabetes (number of years) ()
1–5
21 (5.2)
14.9 (7.6) (13) 0–41
6–10
91 (22.2)
11–15
118 (29.1)
16–20
81 (19.9)
>20
95 (23.4)
Body weight (kg) ()
<50
21 (7.1)
70.9 (19.1) (66.9) 36.8–195.0
50–59
66 (22.5)
60–69
84 (28.6)
70–79
43 (14.6)
≥80
80 (27.2)
Body mass index (BMI) (kg/m2)d ()
<18.5
1 (0.7)
27.9 (5.4) (27.4) 17.2–45.4
18.5–22.9
25 (17.9)
23–27.4
46 (32.9)
≥27.5
68 (48.5)
Waist circumference (cm)b
Male ()
95.5 (11.8) (96.0) 65.0–132.5
<90
20 (27.0)
≥90
54 (73.0)
Female ()
93.8 (18.0) (91.0) 67–204
<80
7 (8.2)
≥80
78 (91.8)
Number of diabetes medications ()
1
94 (20.9)
2.12 (0.8) (2) 1–4
2
224 (49.9)
3
112 (25.0)
4
19 (4.2)
Type of antidiabetes medications ()
Biguanide only
41 (9.1)
Sulphonylurea only
43 (9.6)
Insulin only
16 (3.6)
Biguanide and sulphonylurea
186 (41.4)
Biguanide and insulin
20 (4.5)
Sulphonylurea and insulin
8 (1.8)
Biguanide, sulphonylurea, and insulin
24 (5.3)
Otherse
111 (24.7)
Initial dose of sitagliptin ()
25 mg
34 (7.4)
50 mg
158 (34.6)
100 mg
265 (58.0)
SD: standard deviation. aHbA1c is categorised based on the Clinical Practice Guidelines of Malaysia of <6.5% [5] and the American Diabetes Association of <7% [6]. bFasting blood glucose and waist circumference are categorized based on the Clinical Practice Guidelines of Malaysia [5]. cSome patients may have more than one comorbidity. dBody mass index (BMI) is categorized based on the Clinical Practice Guidelines on Management of Obesity [20]. eOthers include combinations such as meglitinides, thiazolidinediones, and alpha-glucosidase inhibitors.
